Crowdsourcing Clinical Drug Development in a transparent model

1. Crowdsourcing Clinical Drug Developmentin a transparent model Tomasz Sablinski M.D., Ph.D. Founder, Transparency Life Sciences Head of Development, Celtic Therapeutics Open Science Summit Mountain View, CA Oct 23, 2011

2. Perspectives clinical investigator basic researcher - biotech consultant - CRO - big pharma investor entrepreneur

3. the drug development industry is facing extinctionpsychotherapy is not an answer

4. intensive care is the only hope

5. “open innovation”the abuse of terminology

6. Obvious fields:- pre-competitive space- sharing data on: placebo response failed clinical studies

7. Obstacles to crowdsourcing and transparency in pharma legal IP arrogance of experts - fear for loosing jobs - secretive culture antiquated computer sciences development / marketing confluence

8. Drug Development - Sources of Waste partial list……… Attacking the sources of waste + + Pharma Company Infrastructure High-Cost Patient Recruitment Insular Approach to Protocol Design + + = Multiple Patient Visitsto Expensive Sites 20th Century Data Capture & Analyses 8

9. New model:a platform for collecting key information, analyzing it, and building knowledge in a transparent, complete, easy to understand format to enable multiple parties to move a project ahead in a virtual global environment

10. secrecy = legacytransparency = currency

11. Transparency Life Sciencesis a Drug Development Company We acquire IP and pharmaceutical assets from academia, biotech, and pharma, and add significant value by conducting clinical studies via open-source methods, and by executing with unmatched productivity.

12. Passionate About Changing the World of Drug Development Founders Tomasz Sablinski, MD, Ph.D. – Harvard, Novartis, Celtic Rx Marc Foster – FoldRx, Schrodinger, multiple exits in high tech Gareth Hicks, Ph.D. – Cambridge, GSK, Novartis, Tioga Lawrence Steinman, MD – Professor - Stanford, multiple biotechs Advisors Karim Lakhani – Harvard Business School Bernard Munos – Former strategist, Eli Lilly John L. Brown – Former President, Health Properties, Time-Warner Scott Becker – Co-Founder, Invite Media (acquired by Google)

13. Three major enablers:technologysocial changes / culturecrisis

14. TLS Approach Crowd-Sourcing – an approach to protocol design and data analysis, allowing for input from all available stakeholders “10,000 minds are better than 10” Data & Technology Platform – web-based platform integrating multiple real-time data inputs via telemedicine Enhance trial cost-efficiency, safety, data Transparency – Plans, data, analyses are shared openly, in real timeBuilds trust in TLS, provides best analyses

15. How Will it Work in Practice? High-Level View Trial Step Protocol Design Patient Recruit-ment Study Execution Data Collection Analysis Key Leverage Point Crowd-Sourcing Online Groups Tele-medicine Secure,Open Vendors MoreCrowd Input

16. Why do people “go to” work? because of the context ($$ is the major incentive)

17. Why do people contribute? because of their passion for the content ($$ is NOT the major incentive!)

18. Patients web groups Disease foundations Telemedicine companies Genetic testing enterprises Bioinformatics companies Focus: Clinical studies For TLS partnerships are essential

19. Welcome to our project collaborative space !